---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-271449"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-06-15T23:23:08+00:00"
generated_at: "2026-06-16T10:07:33.282619+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio: Michael Kauffman elected Class III director with 96% vote; exec comp, auditor ratified

## Summary
- Michael Kauffman, M.D., Ph.D., elected Class III director with 1,239,169 votes for (96.04%), 0 against, 51,081 withheld.
- Advisory vote on executive compensation approved: 1,242,005 for, 23,606 against, 24,639 abstain.
- Ratification of PricewaterhouseCoopers as auditor for FY 2026: 2,712,825 for, 14,392 against, 7,461 abstain.
- Broker non-votes totaled 1,444,428 on director election and say-on-pay proposals.

## SEC filing metadata
- accession: 0001193125-26-271449
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-06-15T23:23:08+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/0001193125-26-271449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/kynb-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-271449
- JSON: https://secwatch.observer/filing/0001193125-26-271449.json
- Plain text: https://secwatch.observer/filing/0001193125-26-271449.txt

## Key facts
- Shareholder Votes
  KYNTRA BIO, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-12 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement filed on April 27, 2026: 1,242,005 shares of Common Stock voted for, 23,606 against, 24,639 abstaining, and 1,444,428 broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/0001193125-26-271449-index.htm
- Shareholder Votes
  KYNTRA BIO, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-12 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the Kyntra Bio board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2026: 2,712,825 shares of Common Stock voted for, 14,392 against, and 7,461 abstaining.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/0001193125-26-271449-index.htm
- Shareholder Votes
  KYNTRA BIO, INC. shareholders approved Election of Class III director nominee Michael Kauffman, M.D., Ph.D. at the 2026-06-12 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: The Class III director nominee, Michael Kauffman, M.D., Ph.D., was elected to hold office until the Company’s 2029 annual meeting of stockholders. The director received 96.04% of the shares voting: 1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/0001193125-26-271449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.